Sino Biopharm’s chairman reaffirms the company’s ongoing commitment to merger and acquisition activities, signaling a strategic pivot toward consolidating its position in the biopharmaceutical sector. The announcement follows recent corporate restructuring and increased R&D investment.
- Sino Biopharm plans to allocate RMB 1.2 billion ($168 million) for M&A over the next 18 months.
- Company holds 14 investigational drugs, including three in Phase III clinical trials.
- Stock price rose 19% in Q4 2025 amid increased institutional and foreign ownership.
- Foreign ownership now stands at 42%, up from 31% in early 2025.
- Expected acquisition targets include preclinical-stage firms specializing in gene therapy and targeted protein degradation.
Sino Biopharm has confirmed it will maintain active participation in merger and acquisition (M&A) transactions as part of its long-term growth strategy. The statement comes from the company’s Chairman, who emphasized that M&A remains a core component of the firm’s expansion plan, particularly in expanding its pipeline of novel therapeutics and enhancing global market reach. The company disclosed that it has allocated approximately RMB 1.2 billion ($168 million) for potential acquisitions over the next 18 months. This capital deployment reflects a deliberate shift toward acquiring mid-stage biotech assets with strong clinical validation, especially in oncology and autoimmune diseases. Sino Biopharm currently holds a portfolio of 14 investigational drugs in various phases of development, with three candidates in Phase III trials. Market analysts note that the company’s valuation rose by 19% in the last quarter, driven partly by investor confidence in its disciplined M&A approach. The stock, trading under the ticker code 00735.HK, has seen increased institutional interest, with foreign ownership climbing to 42%—up from 31% at the start of 2025. This heightened activity suggests growing market belief in Sino Biopharm’s ability to scale through strategic integration. The decision also underscores broader trends in China’s biopharmaceutical industry, where companies are increasingly relying on external innovation to accelerate drug development. Sino Biopharm is expected to engage in talks with at least three preclinical-stage firms by mid-2026, focusing on technologies related to gene therapy and targeted protein degradation.